NMF has partnered with the Bristol Myers Squibb Foundation (BMSF) to launch the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program (BMSF DCTCDP), an innovative and bold new initiative designed to transform the clinical research landscape by building and strengthening partnerships between clinical investigators and communities to increase diversity of patients enrolled in clinical trials, and ultimately enhance the development of therapeutics for all populations.

This trailblazing 2-year career development program will train and develop 250 new Community-Oriented Clinical Trialists (COCT) to become world-class clinical researchers with the additional knowledge, skills, and competencies to effectively engage with communities to foster active community participation in clinical research. The BMSF DCTCDP will provide sponsorship, support, training, and mentoring for BMSF Scholars to become independent clinical trial investigators who are committed to advancing health equity through their research and mentoring. BMSF Scholars will be trained in investigator-initiated and industry-sponsored clinical trials, as well as in community outreach and engagement processes and methods. Each Scholar will be mentored by an experienced Principal Investigator and will substantively participate in the PI’s active clinical trial.

In addition, the BMSF DCTCDP will build the pipeline of diverse clinical researchers through an investment in 250 students underrepresented in medicine (URM) to participate in a community site-based summer immersion program, the BMSF Clinical Investigator Pipeline Program (CIPP), which is designed to expose students to clinical research career pathways. The BMSF DCTCDP also offers a comprehensive and integrated approach to increase diversity in trial sites through a clinical trial site development infrastructure fund.

Eligible Candidates

BMSF DCTCDP candidates must meet the following eligibility:

  • Hold the degree of MD, MD/PhD, DO or DO/PhD
  • US Citizen or Lawful Permanent Resident (LPR) as defined by the US Department of Homeland Security. (NOTE: O-1 & H-1B Visa holders are eligible; the Visa must be valid throughout the 2-yr program.)
  • Have interest in clinical research in the areas of Cancer, Cardiovascular Disease, and Immunologic Disorders
  • Reflect the NIH definition of Early-Stage Investigator
  • Meet the NSF definition of underrepresented populations in the U.S. Biomedical, Clinical Behavioral and Social Sciences Research Enterprise, or have a demonstrated commitment to increasing diversity in clinical trials

Application Timeline:

  • Letter of Intent opens on October 18, 2021, and closes January 14, 2022, at 11:59pm Eastern Time
  • Full Application opens (by invitation only) on January 31, 2022, and closes April 29, 2022, at 11:59pm Eastern Time
  • Award Notification: August 1, 2022*

* Date subject to change

Click here to submit a Letter of Intent: https://nmf.smapply.io/prog/bmsfdctcdpcohort2

Please visit the program website for more information: www.diversityinclinicaltrials.org.